In response to the global COVID-19 pandemic, Medable has developed a new TeleVisit mobile application that can be used by patients worldwide to connect virtually with their clinical trial sites. The application makes it possible for clinical trial research to progress in an environment where many patients are being told to stay home and avoid social interaction. The application includes the following capabilities:
“We need to reduce the risk for participants while also enabling research to move forward,” said Dr. Michelle Longmire, Co-Founder and CEO of Medable. “There are more than 50,000 active clinical trials underway. These studies are extremely important, and many have been underway for years. We need to ensure participants can receive medical care and evaluation of endpoints during critical study time windows. TeleVisit and decentralized clinical trials enable research to continue while we combat the outbreak with containment measures. We have ensured that we can operationalize this infrastructure on a global scale to support research worldwide.”
Medable’s global TeleVisit application can be used for various decentralized trials and hybrid trials and works with patients’ existing mobile devices as well as tablets used by clinical trial sites. Alternatively, Medable can work with clinical trial teams to provision devices globally, including phones or tablets. Once users download the application, they can connect via one click to a live video stream to discuss personal health developments or concerns.